Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly McGregor

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Clinical Lung Cancer|July 21, 2024
Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung CancerDavid R Gandara, Janakiraman Subramanian, Edgardo S Santos, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2023
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohortTyler J Nielsen, Matthew G Varga, Catherine T Cronister, et al.
NPJ Precision Oncology|August 11, 2023
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testingNadine Tung, Kali Chatham Dougherty, Emily Stern Gatof, et al.
Breast Cancer Research : BCR|July 25, 2024
Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypesArun Kadamkulam Syriac, Nitish Singh Nandu, Allison Clark, et al.
Investigational New Drugs|October 11, 2018
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancerG Weldon Gilcrease, David D Stenehjem, Mark L Wade, et al.
Journal of Translational Medicine|August 16, 2022
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patientsRobert S Seitz, Michael E Hurwitz, Tyler J Nielsen, et al.
International Journal of Cancer|December 18, 2020
Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors casesRichard S P Huang, James Haberberger, Ethan Sokol, et al.
Cancer Medicine|December 14, 2020
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast CancerAbirami Sivapiragasam, Prashanth Ashok Kumar, Ethan S Sokol, et al.
Clinical Genitourinary Cancer|November 17, 2023
The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate CancerWill H Jin, Liangliang Zhang, Ryon Graf, et al.
Lung Cancer (Auckland, N.Z.)|May 6, 2020
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase InhibitorsAlexa B Schrock, Russell Madison, Mark Rosenzweig, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Clinical Lung Cancer|July 21, 2024
Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung CancerDavid R Gandara, Janakiraman Subramanian, Edgardo S Santos, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2023
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohortTyler J Nielsen, Matthew G Varga, Catherine T Cronister, et al.
NPJ Precision Oncology|August 11, 2023
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testingNadine Tung, Kali Chatham Dougherty, Emily Stern Gatof, et al.
Breast Cancer Research : BCR|July 25, 2024
Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypesArun Kadamkulam Syriac, Nitish Singh Nandu, Allison Clark, et al.
Investigational New Drugs|October 11, 2018
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancerG Weldon Gilcrease, David D Stenehjem, Mark L Wade, et al.
Journal of Translational Medicine|August 16, 2022
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patientsRobert S Seitz, Michael E Hurwitz, Tyler J Nielsen, et al.
International Journal of Cancer|December 18, 2020
Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors casesRichard S P Huang, James Haberberger, Ethan Sokol, et al.
Cancer Medicine|December 14, 2020
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast CancerAbirami Sivapiragasam, Prashanth Ashok Kumar, Ethan S Sokol, et al.
Clinical Genitourinary Cancer|November 17, 2023
The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate CancerWill H Jin, Liangliang Zhang, Ryon Graf, et al.
Lung Cancer (Auckland, N.Z.)|May 6, 2020
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase InhibitorsAlexa B Schrock, Russell Madison, Mark Rosenzweig, et al.
Pageof 3